BatesD.W., SchmittW., BuchwaldD., WareN.C., LeeJ., ThoyerE., KornishR.J. and KomaroffA.L.1993. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice.Arch. Intern. Med.153:2759.
2.
BennettR.2005. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses.Clin. Exp. Rheumatol.23(S):154.
3.
ZachrissonO., ReglandB., JahreskogM., KronM. and GottfriesC.G.2002. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale).J. Psychosom. Res.52:501.
4.
BennettR.2004. Fibromyalgia: present to future.Curr. Pain Headache Rep.8:379.
5.
PongratzD.E. and SieversM.2000. Fibromyalgia-symptom or diagnosis: a definition of the position.Scands. J. Rheumatol.113(S):3.
6.
RauC. L. and RussellI.J.2000. Is fibromyalgia a distinct clinical syndrome?Curr. Rev. Pain4:287.
7.
ThiemeK., SpiesC., SinhaP., TurkD.C. and FlorH.2005. Predictors of pain behaviors in fibromyalgia syndrome.Arthritis Rheum.53:343.
ArnoldL.M., HudsonJ.I., HessE.V., WareA.E., FritzD.A., AuchenbachM.B., StarckL.O. and KeckP.E.Jr.2004. Family study of fibromyalgia.Arthritis Rheum.50:944.
10.
MeaseP.2005. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.J. Rheumatol.75(S):6.
11.
NeeckG.2002. Pathogenic mechanisms of fibromyalgia.Ageing Res. Rev.1:243.
12.
TheoharidesT. C. and CochraneD.E.2004. Critical role of mast cells in inflammatory diseases and the effect of acute stress.J. Neuroimmunol.146:1.
13.
VanH. B. and EgleU.T.2004. Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together.Psychother. Psychosom.73:267.
14.
KhasarS.G., GreenP.G. and LevineJ.D.2005. Repeated sound stress enhances inflammatory pain in the rat.Pain116:79.
15.
SchwarzM.J., SpathM., Muller-BardorffH., PongratzD.E., BondyB. and AckenheilM.1999. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients.Neurosci. Lett.259:196.
16.
MullingtonJ.M., Hinze-SelchD. and PollmacherT.2001. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions.Ann. N.Y. Acad. Sci.933:201.
17.
GurA., KarakocM., ErdoganS., NasK., CevikR. and SaracA.J.2002. Regional cerebral blood flow and cytokines in young females with fibromyalgia.Clin. Exp. Rheumatol.20:753.
18.
WallaceD.J., Linker-IsraeliM., HalleguaD., SilvermanS., SilverD. and WeismanM.H.2001. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study.Rheumatology40:743.
19.
TorpyD.J., PapanicolaouD.A., LotsikasA.J., WilderR.L., ChrousosG.P. and PillemerS.R.2000. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia.Arthritis Rheum.43:872.
20.
GurA., KarakocM., NasK., CevikRemzi, DenliA. and SaracJ.2002. Cytokines and depression in cases with fibromyalgia.J. Rheumatol.29:358.
21.
TheoharidesT.C., DonelanJ.M., PapadopoulouN., CaoJ., KempurajD. and ContiP.2004. Mast cells as targets of corticotropin-releasing factor and related peptides.Trends Pharmacol. Sci.25:563.
22.
CaoJ., PapadopoulouN., KempurajD., BoucherW.S., SugimotoK., CetruloC.L. and TheoharidesT.C.2005. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor (VEGF).J. Immunol.174:7665.
23.
Kandere-GrzybowskaK., LetourneauR., BoucherW., BeryJ., KempurajD., PoplawskiS., AthanassiouA. and TheoharidesT.C.2003. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells.J. Immunol.171:4830.
24.
EnestromS., BengtssonA. and FrodinT.1997. Dermal IgG deposits and increase of mast cells in patients with fibromyalgia-relevant findings or epiphenomena?Scand. J. Rheumat.26:308.
25.
SalemiS., RethageJ., WollinaU., MichelB.A., GayR.E., GayS. and SprottH.2003. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia.J. Rheumatol.30:146.
26.
De StefanoR., SelviE., VillanovaM., FratiE., ManganelliS., FranceschiniE., BiasiG. and MarcolongoR.2000. Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome.J. Rheumatol.27:2906.
27.
LytinasM., KempurajD., HuangM., BoucherW., EspositoP. and TheoharidesT.C.2003. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.Int. Arch. Allergy Immunol.130:224.
28.
SinghL.K., PangX., AlexacosN., LetourneauR. and TheoharidesT.C.1999. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: A link to neurogenic skin disorders.Brain Behav. Immunity13:225.
29.
TheoharidesT.C., SinghL.K., BoucherW., PangX., LetourneauR., WebsterE. and ChrousosG.1998. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects.Endocrinology139:403.
30.
Kandere-GrzybowskaK., GheorgheD., PrillerJ., EspositoP., HuangM., GerardN. and TheoharidesT.C.2003. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice.Brain Res.980:213.
31.
MilleaP. J. and HollowayR.L.2000. Treating fibromyalgia.Am. Fam. Physician62:1575.
32.
DadabhoyD. and ClauwD.J.2005. Fibromyalgia: progress in diagnosis and treatment.Curr. Pain Headache Rep.9:399.
33.
RussellI.J., VipraioG.A., MichalekJ.E., CraigF.E., KangY.K. and RichardsA.B.1999. Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha.J. Interferon Cytokine Res.19:969.
34.
MullerW. and StratzT.2004. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.Scand. J. Rheumatol.119(S):44.
35.
StratzT., FiebichB., HausU. and MullenW.2004. Influence of tropisetron on the serum substance P levels in fibromyalgia patients.Scand. J. Rheumatol.119(S):41.
36.
SpathM.2002. Current experience with 5-HT3 receptor antagonists in fibromyalgia.Rheum. Dis. Clin. North Am.28:319.
37.
BakerK. and BarkhuizenA.2005. Pharmacologic treatment of fibromyalgia.Curr. Pain Headache Rep.9:301.
38.
TheoharidesT.C. and BieloryL.2004. Mast cells and mast cell mediators as targets of dietary supplements.Ann. Allergy Asthma Immunol.93.S24.
39.
MiddletonE.Jr., KandaswamiC. and TheoharidesT.C.2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer.Pharmacol. Rev.52:673.
40.
KempurajD., MadhappanB., ChristodoulouS., BoucherW., CaoJ., PapadopoulouN., CetruloC.L. and TheoharidesT.C.2005. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells.Br. J. Pharmacol.145:934.
41.
TheoharidesT.C., PatraP., BoucherW., LetourneauR., KempurajD., ChiangG., JeudyS., HesseL. and AthanasiouA.2000. Chondroitin sulfate inhibits connective tissue mast cells.Br. J. Pharmacol.131:1039.
42.
TheoharidesT. C.2003. Dietary supplements for arthritis and other inflammatory conditions: key role of mast cells and benefit of combining anti-inflammatory and proteoglycan products.Eur. J. Inflamm.1:1.
